Edesa Biotech, Inc.
9.0M
$93.25M
-1.95
$-1.27
No price alerts set. Add an alert to get notified!
-1.95
1.13
$-1.27
-57.71%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
$0.23 | 1.22% | -0.15 | $2.09M | 0.00 |
|
COCP
Cocrystal Pharma, Inc.
|
$1.40 | -2.10% | -1.79 | $14.35M | 0.24 |
|
DWTX
Dogwood Therapeutics, Inc.
|
$1.34 | -2.90% | -0.57 | $2.56M | 0.00 |
|
ERNA
Ernexa Therapeutics Inc.
|
$0.20 | 4.33% | -0.11 | $1.57M | 0.20 |
|
EVGN
Evogene Ltd.
|
$0.78 | -1.00% | -0.81 | $6.15M | -26.80 |
|
IMNN
Imunon, Inc.
|
$2.80 | 0.36% | -0.41 | $7.06M | 0.14 |
|
IMRN
Immuron Limited
|
$0.87 | -2.53% | -1.83 | $5.61M | 0.00 |
|
OSRH
OSR Holdings, Inc.
|
$0.72 | 4.44% | -0.15 | $18.58M | 0.06 |
|
SNSE
Sensei Biotherapeutics, Inc.
|
$31.54 | -0.79% | -1.89 | $42.27M | 0.08 |
|
TRAW
Traws Pharma, Inc.
|
$1.14 | -1.72% | -2.56 | $9.38M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$11.87
$0.72
$0.00
0.00%
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
